Announcements Trials
Browse Landscape

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Gastrointestinal 36Thoracic 21Lymphoid 5Sarcoma 4Head & Neck 4Gynecologic 4CNS 4Other hematologic neoplasm 3Genitourinary 3Breast 2Plasma cell 1Other solid neoplasm 1NET 1Myeloid 1Endocrine 1Dermatologic 1

Conditions

Neuroendocrine Tumors 378Pituitary Neoplasms 159Multiple Endocrine Neoplasia Type 1 150Thyroid Cancer, Papillary 122Pheochromocytoma 107Carcinoma, Neuroendocrine 93Thyroid Neoplasms 74Paraganglioma 68Carcinoid Tumor 66Neoplasms 54Thyroid Carcinoma, Anaplastic 50Adrenocortical Carcinoma 47Adrenal Gland Neoplasms 46Neoplasm Metastasis 40Insulinoma 39Pancreatic Neoplasms 36Gastro-enteropancreatic neuroendocrine tumor 36Adenoma, Islet Cell 36Carcinoma, Medullary 29Neuroblastoma 28Adenocarcinoma, Follicular 28Hyperaldosteronism 25Prostatic Neoplasms 24Lung Neoplasms 24Obesity 23Brain Neoplasms 22Pituitary Diseases 21Differentiated Thyroid Cancer 20Cushing Syndrome 20Sarcoma 19

Interventions

telotristat ethyl 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Cachexia × Endocrine × Clear all
NCT04034745 2020-12-30

Open Label Study to Analyze the Effect of Telotristat Ethyl on Weight Regulation/Gain

Cedars-Sinai Medical Center

Withdrawn
EndocrineGastrointestinalNET

Cachexia, Neoplasms, Pancreatic Neoplasms, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡